Abstract
Since the advent of the Moderna and Pfizer-BioNTech COVID-19 vaccines, RNA-based drug and vaccine candidates have garnered significant cash and attention. RNA is a hot topic. According to the team at Resalis Therapeutics , it’s also a hot target. The Italy-based company launched Feb. 22 with €10 million ($10.7 million) to develop therapies targeting noncoding RNA to treat metabolic diseases. Noncoding RNA is RNA that does not get translated into a protein. One such type, microRNA, gloms onto a strand of messenger RNA (mRNA) and blocks a portion of that strand from being translated. As the name suggests, microRNAs are very small—usually around 20–24 nucleotides—and they can bind to several different mRNAs, says Riccardo Panella, a Resalis cofounder and its chief scientific officer. With its lead candidate, Resalis is targeting microRNA-22 (miR-22). “We say it’s the master regulator of metabolism,” says Sakari Kauppinen, also a cofounder, as well as Resalis’s
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
